Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit – MRK

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud that affected investors between February 3, 2022, and February 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by misleading information regarding expected revenue of $11 billion from Gardasil sales by 2030 [2]. - Defendants expressed confidence in Merck's ability to drive demand for Gardasil through consumer education efforts, which led to optimistic forecasts for its growth in China [2]. - On February 4, 2025, Merck announced it would not meet the projected$11 billion in sales due to ceasing shipments to China, resulting in a significant stock price drop from $99.79 to$90.74, a decline of over 9% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].